VCELVericel Corporation

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M+10.7% YoY

Gross Profit

$38M72.6% margin

Operating Income

$6M11.5% margin

Net Income

$6M11.2% margin

EPS (Diluted)

$0.12

QoQ Revenue Growth

+36.7%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$6M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$273M

Total Liabilities

$81M

Stockholders' Equity

$192M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$48M	+10.7%
Gross Profit	$38M	$34M	+12.4%
Operating Income	$6M	$4M	+46.9%
Net Income	$6M	$5M	+30.6%

VCEL Q4 2022 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena